Epizyme Announces Date of Fourth Quarter and Full Year 2018 Results and Upcoming Presentation at the 8th Annual SVB Leerink Global Health Care Conference

. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company
creating novel epigenetic therapies, today announced that management
will host a conference call in conjunction with the announcement of its
fourth quarter and full-year 2018 financial results and present at the 8th
Annual Leerink Partners Health Care Conference. Details of both events
are as follows:

  • Fourth Quarter and Full-Year 2018 Financial Results: Management
    will host a conference call and webcast to discuss its fourth quarter
    and full year 2018 financial results and other business highlights
    at 8:30 a.m. ET on Tuesday, February 26, 2019. To participate in the
    conference call, please dial (877) 844-6886 (domestic) or (970)
    315-0315 (international) and refer to conference ID 1088195.
  • 8th Annual SVB Leerink Global Health Care
    Conference Presentation:
     Management will present a company
    overview at the 8th Annual SVB Leerink Global Health Care
    Conference on Thursday, February 28, 2019 at 2:30 p.m. ET in New York

Live webcasts will be available in the investor section of the company’s
website at www.epizyme.com.
The webcasts also will be archived for 60 days following the call and

About Epizyme, Inc.

Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to
rewriting treatment for cancer and other serious diseases through novel
epigenetic medicines. Epizyme is broadly developing its lead product
candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies
underway in both solid tumors and hematological malignancies, as a
monotherapy and combination therapy in relapsed and front-line disease.
The company also is developing a novel G9a program with its next
development candidate, EZM8266, which is targeting sickle cell disease.
By focusing on the genetic drivers of disease, Epizyme’s science seeks
to match targeted medicines with the patients who need them. For more
information, visit www.epizyme.com.


Erin Graves, Epizyme, Inc.

Monique Allaire, THRUST Strategic

error: Content is protected !!